Status:
COMPLETED
Weaning From Nasal High Flow Therapy
Lead Sponsor:
Hôpital Louis Mourier
Conditions:
Respiratory Distress Syndrome, Adult
Acute Hypoxemic Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
Nasal high flow is widely used in critically ill patients admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure. It has been shown to improve patient comfort, increase oxyg...
Detailed Description
Although nasal high flow is widely used in critically ill patients admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure, and its benefits have been shown in multiple studi...
Eligibility Criteria
Inclusion
- \- ICU patient treated with nasal high flow
Exclusion
- age \< 18 years
- concomitant treatment with non-invasive ventilation
- acute hypercapnic respiratory failure
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05210881
Start Date
January 1 2019
End Date
August 31 2021
Last Update
January 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris
Colombes, France, 92700